GlobeNewswire Inc | Jan 4, 2021 06:00AM EST

January 04, 2021

Correction to inclusion/exclusion criteria for eIND authorization

VANCOUVER, Washington, Jan. 04, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Mahboob Rahman, M.D., Ph.D., Chief Scientific Officer, will host an investment community webcast on Wednesday, January 6, 2021.

Management will provide an update on recent clinical and regulatory developments regarding COVID-19 clinical trials, along with other strategic priorities:

1) BLA/MAA submissions to Health Canada, MHRA, EMA, and US FDA2) HIV prevention trial/monotherapy trial3) Potential revenue from HIV and manufacturing forecast4) HIV Cure - amfAR5) EUA submission timelines to same four agencies for COVID-19, if CD12 Trial results are supportive of an EUA6) Long-hauler clinical trial and potential data readout timelines7) NASH trial and potential interim analysis timeline8) Cancer trial Breakthrough Therapy designation potential timelines9) GvHD trial status10) Stroke/MS new trials in 202111) NASDAQ uplisting status

Management will also provide approximately 30-45 minutes to address questions submitted online by analysts and investors.

Date: Wednesday, January 6, 2021Time: 1:00 pm PT / 4:00 pm ETDial-In: None.Questions:

-- Prior to the webcast, questions can be submitted online to CYDY_Team@cytodyn.com -- During the webcast, questions can be submitted through the webcast link below.

This is a listen only webcast, which can be accessed via CytoDyns corporate website atwww.cytodyn.comunder the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. The webcast can also be accessed via the following link:

https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/42723/indexl.html

The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until February 6, 2021.

Correction In a press release dated December 30, 2020, the Company specified certain subgroups of patients will be excluded from the eIND authorization process. The second subgroup is now corrected as: mechanically ventilated with PEEP >=15 cmH20 with Pa02/FiO2 <=150 mmHg.

CONTACTSInvestors: Michael MulhollandOffice: 360.980.8524, ext. 102mmulholland@cytodyn.com